Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Alvin Yu-Jin Ng, PhD, Benedict Yan, MBBS, Wee-Joo Chng, MBBS, PhD

Blood (2019) 134 (Supplement_1): 5177.

https://doi.org/10.1182/blood-2019-127727

Published: 2019

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Blood (2016) 128 (22): 1891.

https://doi.org/10.1182/blood.V128.22.1891.1891

Published: 2016

Journal Articles

A Case of Two Young Brothers with Natural-Killer/T-Cell Lymphoma

Tiffany Tang, MD, Maarja-Liisa Nairismagi, PhD, Alvin Yu Jin Ng, PhD, Byrappa Venkatesh, Joanne Ngeow, MD, Shao-Tzu Li, Yurike Laurensia, BSc, Jing Quan Lim, PhD, Sanjanaa Nagarajan, MSc, Burton Chia, Jing Tan, PhD, Yeow Tee Goh, MD, Miriam Tao, MD, Richard Hong Hui Quek, MD, Mohamad Farid, MD, Soon Thye Lim, MD, Choon Kiat Ong

Blood (2016) 128 (22): 5293.

https://doi.org/10.1182/blood.V128.22.5293.5293

Published: 2016

Journal Articles

Can Memory T Cell Monitoring Using Flow Cytometry Predict Survival in Haploidentical Hematopoietic Stem Cell Transplantation?

Bohyun Kim, MD PhD, Seongsoo Jang, MD PhD, Yu-Jin Lee, Young-Uk Cho, MD PhD, Chan-Jeoung Park, MD PhD, Eun-Seok Choi, Kyung-Nam Koh, MD PhD, Ho Joon Im, MD PhD, Jong Jin Seo, MD PhD

Blood (2016) 128 (22): 4591.

https://doi.org/10.1182/blood.V128.22.4591.4591

Published: 2016

Journal Articles

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Carla Maria Boquimpani, Naoto Takahashi, MD PhD, Noam Benyamini, MD, Nelma Cristina D Clementino, MD, Vasily Shuvaev, MD, Sikander Ailawadhi, MD, Jeffrey H. Lipton, MD PhD, Anna G Turkina, Prof., MD, Elena Beatriz Moiraghi, MD, Franck E. Nicolini, MD PhD, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, MD PhD, Rafik Fellague-Chebra, MD MSc, Sandip Acharya, MSc, Nancy Krunic, PhD, Yu Jin, MS, François-Xavier Mahon, MD PhD

Blood (2016) 128 (22): 792.

https://doi.org/10.1182/blood.V128.22.792.792

Published: 2016

Journal Articles

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Marco Aurelio Salvino, MD PhD, Ong Tee Chuan, MD, Alaa Elhaddad, MD PhD, Kudrat Abdulkadyrov, MD PhD, Jake Shortt, MD, Hang Quach, MD, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Lee-Yung Shih, MD, Anna G. Turkina, MD PhD, Luis Meillon, MD, Yu Jin, MS, Sadhvi Khanna, MS, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 344.

https://doi.org/10.1182/blood.V126.23.344.344

Published: 2015

Journal Articles

Lineage-Specific Chimerism Monitoring Using Flow Cytometry with Anti HLA-Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation

Bo Hyun Kim, MD, Seongsoo Jang, MD PhD, Yu-jin Lee, Nuree Park, Young-Uk Cho, MD PhD, Chan-Jeoung Park, MD PhD, Eun-Seok Choi, Jin-Kyung Seo, Seong-Uk Lee, Kyung-Nam Koh, MD PhD, Ho Joon Im, MDPhD, Jong Jin Seo, MD

Blood (2014) 124 (21): 3921.

https://doi.org/10.1182/blood.V124.21.3921.3921

Published: 2014

Journal Articles

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jeff H. Lipton, PhD, MD, Luis Meillon, MD, Vernon Louw, MD, Carolina Pavlovsky, MD, Lee-Yung Shih, MD, Yu Jin, Sandip Acharya, Richard C. Woodman, Timothy P. Hughes, MD, Anna G. Turkina, MD, PhD

Blood (2013) 122 (21): 4009.

https://doi.org/10.1182/blood.V122.21.4009.4009

Published: 2013

Journal Articles

AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura

Sheng-Yu Jin, Juan Xiao, Jialing Bao, Shangzhen Zhou, J. Fraser Wright, X. Long Zheng

Blood (2013) 121 (19): 3825–3829.

https://doi.org/10.1182/blood-2013-02-486779

Published: 2013

Includes: Supplemental data

Journal Articles

Ectopic Expression of ADAMTS13 in Platelets As a Novel Therapeutic Approach for Arterial Thrombosis

Brandy Pickens, PhD, Sheng-Yu Jin, MD, PhD, Dengju Li, MD, PhD, X. Long Zheng, MD, PhD

Blood (2012) 120 (21): 491.

https://doi.org/10.1182/blood.V120.21.491.491

Published: 2012

Journal Articles

Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice

Aleksandra Wroblewska, Simon D. van Haren, Eszter Herczenik, Paul Kaijen, Aleksandra Ruminska, Sheng-Yu Jin, X. Long Zheng, Maartje van den Biggelaar, Anja ten Brinke, Alexander B. Meijer, Jan Voorberg

Blood (2012) 119 (22): 5294–5300.

https://doi.org/10.1182/blood-2011-11-391680

Published: 2012

Includes: Supplemental data

Journal Articles

Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura

Cui Jian, Juan Xiao, Lingjie Gong, Christopher G. Skipwith, Sheng-Yu Jin, Hau C. Kwaan, X. Long Zheng

Blood (2012) 119 (16): 3836–3843.

https://doi.org/10.1182/blood-2011-12-399501

Published: 2012

Includes: Multimedia, Supplemental data

Journal Articles

Gain-of-Function ADAMTS13 Variants Resistant to Anti-ADAMTS13 Autoantibody Inhibition: A Potential Novel Therapy for Acquired Autoimmune Thrombotic Thrombocytopenic Purpura

Cui Jian, M.S., Juan (Jenny) Xiao, M.D., Ph.D., Lingjie Gong, M.D., Christopher G. Skipwith, Sheng-Yu Jin, M.D., Ph.D., Hau C. Kwaan, M.D., Ph.D., X. Long Zheng, M.D., Ph.D.

Blood (2011) 118 (21): 1188.

https://doi.org/10.1182/blood.V118.21.1188.1188

Published: 2011

Journal Articles

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Susan Branford, PhD, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, PhD, Yu Jin, Richard C. Woodman, MD, Fabrizio Pane, MD, Dong-Wook Kim, Jerald P. Radich, MD, Timothy P. Hughes

Blood (2010) 116 (21): 889.

https://doi.org/10.1182/blood.V116.21.889.889

Published: 2010

Journal Articles

Multiple Carboxyl-Terminal Domains of ADAMTS13 Are Required for Systemic Anti-Arterial Thrombosis In Vivo

Juan (Jenny) Xiao, M.D., Ph.D., Sheng-Yu Jin, M.D., Ph.D., X. Long Zheng, M.D., Ph.D.

Blood (2010) 116 (21): 24.

https://doi.org/10.1182/blood.V116.21.24.24

Published: 2010

Journal Articles

Correction of ADAMTS13 Deficiency by AAV-Mediated Gene Transfer of a C-Terminal Truncated ADAMTS13 Variant In a Murine Model

Sheng-Yu Jin, M.D., Ph.D., Juan (Jenny) Xiao, M.D., Ph.D., J. Fraser Wright, Ph.D., X. Long Zheng, M.D., Ph.D.

Blood (2010) 116 (21): 251.

https://doi.org/10.1182/blood.V116.21.251.251

Published: 2010

Journal Articles

Amino acid residues Arg 659 , Arg 660 , and Tyr 661 in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor

Sheng-Yu Jin, Christopher G. Skipwith, X. Long Zheng

Blood (2010) 115 (11): 2300–2310.

https://doi.org/10.1182/blood-2009-07-235101

Published: 2010

Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD

Blood (2009) 114 (22): 1127.

https://doi.org/10.1182/blood.V114.22.1127.1127

Published: 2009

Journal Articles

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, MD, Brian J. Druker, MD, Jorge Cortes-Franco, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Fabrizio Pane, Susan Branford, PhD, Yu Jin, MSc, Tillmann Krahnke, PhD, Marc Rudoltz, MD, Jerald P. Radich, MD, François Guilhot, MD

Blood (2009) 114 (22): 337.

https://doi.org/10.1182/blood.V114.22.337.337

Published: 2009

Journal Articles

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Vi j ay Modur, MD, PhD, Dean C Bottino, PhD, Susan Branford, PhD, Tillmann Krahnke, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Yu Jin, Timothy P Hughes, MD, Dong-Wook Kim, MD, PhD, Jerald Radich, MD, J. Carl Barrett, PhD

Blood (2008) 112 (11): 2124.

https://doi.org/10.1182/blood.V112.11.2124.2124

Published: 2008

NARROW

Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

A Case of Two Young Brothers with Natural-Killer/T-Cell Lymphoma

Can Memory T Cell Monitoring Using Flow Cytometry Predict Survival in Haploidentical Hematopoietic Stem Cell Transplantation?

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Lineage-Specific Chimerism Monitoring Using Flow Cytometry with Anti HLA-Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura

Ectopic Expression of ADAMTS13 in Platelets As a Novel Therapeutic Approach for Arterial Thrombosis

Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice

Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura

Gain-of-Function ADAMTS13 Variants Resistant to Anti-ADAMTS13 Autoantibody Inhibition: A Potential Novel Therapy for Acquired Autoimmune Thrombotic Thrombocytopenic Purpura

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Multiple Carboxyl-Terminal Domains of ADAMTS13 Are Required for Systemic Anti-Arterial Thrombosis In Vivo

Correction of ADAMTS13 Deficiency by AAV-Mediated Gene Transfer of a C-Terminal Truncated ADAMTS13 Variant In a Murine Model

Amino acid residues Arg 659 , Arg 660 , and Tyr 661 in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only